SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT07597902
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Valacyclovir — DRUG
    one to two 750mg capsules taken orally in the morning and evening
  • Celecoxib — DRUG
    200mg capsules taken orally in the morning and evening
  • Paxlovid — DRUG
    one (100mg ritonavir tablet and two 150mg nirmatrelvir tablets) taken orally in the morning and evening
  • Placebo — DRUG
    matching placebo capsules and tablets taken orally in the morning and evening

Study Details

The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).

Key Dates

Start date
Jun 1, 2026
Status verified
Feb 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Combination Drug Therapy
    For 14 weeks, receives valacyclovir and celecoxib initially, then addition of Paxlovid for 15 days while decreasing valacyclovir dose, and then returns to valacyclovir at the original dose later.
  • Placebo Comparator: Placebo
    For 14 weeks, receives matched placebo capsules and tablets

Primary Outcome Measure

EQ-5D-5L Visual Analogue Scale (VAS) [ Time Frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)New YorkNew York10029
David Putrino, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)· New York, NY

Related Studies